RESUMEN
A bioassay-guided phytochemical study of a Mimosa caesalpiniifolia leaf extract with antifungal activity permitted the identification of 28 compounds, including the new 6-(ß-boivinopyranosyl)apigenin (1), 8-(ß-oliopyranosyl)apigenin (2), (E)-6-(2-carboxyethenyl)apigenin (3), (E)-8-(2-carboxyethenyl)apigenin (4), and 7,5â³-anhydro-6-(α-2,6-dideoxy-5-hydroxyarabinohexopyranosyl)apigenin (5). The structures of the new compounds were determined by comprehensive spectroscopic analysis, including 1D and 2D NMR techniques, and by mass spectrometry. Compound 3 showed promising activity and selectivity against Candida krusei (IC50 44 nM), which exhibits resistance to azoles. The association of the major components 3-ß-d-glucopyranosyloxysitosterol (8) and ethyl gallate (10) was synergistic against C. krusei, especially the IC values of compound 10, which were reduced by more than 100-fold.
RESUMEN
Fungal infections represent a serious health risk as they are particularly prevalent in immunocompromised individuals. Candida spp. pathogenicity depends on several factors and secreted aspartic proteinases (Sap) are considered one of the most critical factors as they are associated with adhesion, invasion and tissue damage. The production of proteinases is encoded by a family of 10 genes known as SAP, which are distributed differently among the species. The expression of these genes may be influenced by environmental conditions, which generally result in a higher fungal invasive potential. Non-pathogenic Candida spp. usually have fewer SAP genes, which are not necessarily expressed in the genome. Exposure to subinhibitory concentrations of antifungal agents promotes the development of resistant strains with an increased expression of SAP genes. In general, Candida spp. isolates that are resistant to antifungals show a higher secretion of Sap than the susceptible isolates. The relationship between Sap secretion and the susceptibility profile of the isolates is of great interest, although the role of SAPs in the development of resistance to antifungal agents remains still unclear. This review is the first one to address these issues.
Asunto(s)
Antifúngicos/farmacología , Proteasas de Ácido Aspártico/metabolismo , Candida/enzimología , Candida/patogenicidad , Farmacorresistencia Fúngica , Proteínas Fúngicas/metabolismo , Micosis/microbiología , Animales , Proteasas de Ácido Aspártico/genética , Candida/efectos de los fármacos , Proteínas Fúngicas/genética , Humanos , Micosis/tratamiento farmacológico , VirulenciaRESUMEN
Six derivatives of guttiferone-A (LFQM-79, 80, 81, 82, 113 and 114) were synthesized and evaluated for their antimicrobial activity against the opportunistic or pathogenic fungi Candida albicans (ATCC 09548), Candida glabrata (ATCC 90030), Candida krusei (ATCC 6258), Candida parapsilosis (ATCC 69548), Candida tropicalis (ATCC 750), Cryptococcus neoformans (ATCC 90012), Trichophyton tonsurans, Microsporum gypseum and also against the opportunistic and pathogenic Gram-positive bacteria Staphylococcus aureus (ATCC 6538), Staphylococcus epidermidis (ATCC 12228), Bacillus cereus (ATCC 11778) and Gram-negative Escherichia coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 9027), Salmonella typhimurium (ATCC 14028), Proteus mirabilis (ATCC 25933). The antimicrobial activities of derivatives were compared with guttiferone-A and they presented to be more potent than the original molecule and sometimes greater than standard drugs established in therapeutics. The current study showed that derivatives of guttiferone-A possess potent antimicrobial activity and are relatively non-cytotoxic, which reveal these new molecules as promising new drug prototype candidates, with innovative structural pattern.
Asunto(s)
Antibacterianos/síntesis química , Antibacterianos/farmacología , Antifúngicos/síntesis química , Antifúngicos/farmacología , Bacterias/efectos de los fármacos , Benzofenonas/farmacología , Hongos/efectos de los fármacos , Antibacterianos/química , Antifúngicos/química , Bacterias/crecimiento & desarrollo , Benzofenonas/síntesis química , Benzofenonas/química , Supervivencia Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Hongos/crecimiento & desarrollo , Humanos , Leucocitos Mononucleares/citología , Leucocitos Mononucleares/efectos de los fármacos , Pruebas de Sensibilidad Microbiana , Conformación Molecular , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
The increased incidence of infections caused by the opportunistic pathogen Cryptococcus neoformans, which mainly affects immunocompromised patients but can also infect immunocompetent individuals, has needed additional studies on this micro-organism's pathogenicity and factors related to virulence, such as enzyme production, for a better understanding of the aetiology of cryptococcosis. The aim of this study was to verify the applicability of non-denaturing PAGE for analysis of laccases by quantification of the amount of melanin pigment produced by clinical and environmental strains of C. neoformans. After incubation of the gel with the substrate L-dopa, strains produced melanin spots of a bright brown to black colour. Quantification of these spots was performed by densitometry analysis and the amount of melanin produced was calculated and compared among the strains. All strains showed laccase activity. Serotype B strains showed a higher melanin intensity than serotype A strains. Over half of the clinical strains (56.2%) showed the lowest melanin intensities, suggesting that melanin production may not be the main virulence factor against host defence. The clinical strain ICB 88 revealed two melanin spots on the gel, indicating the presence of two laccase isoforms. The environmental strains showed the highest values of melanin intensity, which may be related to previous exposure to environmental stress conditions.
Asunto(s)
Criptococosis/microbiología , Cryptococcus neoformans/fisiología , Lacasa/metabolismo , Melaninas/biosíntesis , Brasil , Criptococosis/inmunología , Cryptococcus neoformans/clasificación , Cryptococcus neoformans/enzimología , Cryptococcus neoformans/aislamiento & purificación , Humanos , Huésped Inmunocomprometido , SerotipificaciónRESUMEN
This study compared the minimum inhibitory concentration (MIC) results from the proposed standard methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing (AFST-EUCAST) with the commercial system Etest(R) in the evaluation of susceptibility to flucytosine, fluconazole, itraconazole, voriconazole, and amphotericin B of 136 Candida spp. isolated from the blood of hospitalized children. The results presented a greater agreement among Etest(R) MICs +/-2 log2 dilutions of AFST-EUCAST for fluconazole (98.1% and 96.3%) and voriconazole (100% and 100%) for Candida albicans and Candida parapsilosis. For Candida glabrata, the agreement was greater only for fluconazole (81.8%) and voriconazole (100%). For amphotericin B, the agreement between the methods was low for all species. The agreement percentage among the Etest(R) and AFST-EUCAST susceptibility profiles was high according to the MIC breakpoints recommended by the M27-A2 protocol for the majority of the yeasts, except for fluconazole and itraconazole against Candida tropicalis and for itraconazole against C. glabrata and Candida krusei. According to both methodologies, a great number of Candida spp. isolates showed an in vitro susceptibility to all evaluated antifungal agents. Overall, both procedures can be reliable techniques for susceptibility tests of yeasts, but the assessment of interlaboratory agreement and correlation of MICs by different methods with in vivo response are of great importance.
Asunto(s)
Antifúngicos/farmacología , Sangre/microbiología , Candida/efectos de los fármacos , Pruebas de Sensibilidad Microbiana/métodos , Anfotericina B/farmacología , Brasil , Candida/aislamiento & purificación , Niño , Preescolar , Fluconazol/farmacología , Flucitosina/farmacología , Hospitales Públicos , Humanos , Lactante , Recién Nacido , Itraconazol/farmacología , Pirimidinas/farmacología , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Triazoles/farmacología , VoriconazolRESUMEN
A prospective study was performed to evaluate the correlation between the proposed standard of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing (AFST-EUCAST) (document 7.1) and the commercial system Etest for determining the MICs of flucytosine, amphotericin B, fluconazole, itraconazole and voriconazole for a collection of 100 clinical and environmental isolates of Cryptococcus neoformans. The agreements among Etest MICs within +/-2 log2 dilutions of AFST-EUCAST standard MICs were greater for flucytosine, fluconazole and voriconazole (76, 78 and 88 %, respectively) than for amphotericin B (5 %), the lowest agreement, and itraconazole (67 %). Overall, the correlation coefficients were statistically significant (P<0.05), and it is suggested that the Etest and AFST-EUCAST method are reliable alternatives and present good correlation for all drugs evaluated except amphotericin B. However, the observed differences related to MICs for susceptible, susceptible dose dependent and resistant strains between the methods suggest that it will be necessary to carry out further studies, including assessment of interlaboratory agreement and correlation of MICs by different methods with in vivo response.
Asunto(s)
Criptococosis/microbiología , Cryptococcus neoformans/efectos de los fármacos , Pruebas de Sensibilidad Microbiana/métodos , Antifúngicos/farmacología , Brasil , Humanos , Juego de Reactivos para Diagnóstico , Sensibilidad y EspecificidadRESUMEN
This study involved a total of 116 samples, 79 taken from pigeon droppings and 37 of atmospheric air taken close to accumulations of excrement. Cryptococcus neoformans var. grubii was isolated from 11 (13.9%) of these samples. Other species of Cryptococcus were also isolated from these samples, such as C. albidus (12.6%) and C. laurentii (8.9%). C. neoformans was not isolated from the air samples, though C. albidus (5.4%) was. All the strains of C. neoformans were found to belong to the A serotype (C. neoformans var. grubii). In regard to the studies with the antifungal agents 5-fluorocytosine, fluconazole, itraconazole, amphotericin B and voriconazole, by means of the microdilution method (EUCAST), we point out that one sample demonstrated resistance to fluconazole, this being especially significant because this is an environmental strain.
Asunto(s)
Microbiología del Aire , Antifúngicos/farmacología , Cryptococcus neoformans/aislamiento & purificación , Heces/microbiología , Animales , Brasil , Columbidae , Cryptococcus neoformans/efectos de los fármacos , Pruebas de Sensibilidad MicrobianaRESUMEN
Analisaram-se 116 amostras, sendo 79 de fezes de pombos e 37 de ar atmosférico de regiões com acúmulo de fezes. Isolou-se Cryptococcus neoformans var. neoformans de 11 (13.9%) destas amostras. Outras espécies de Cryptococcus também foram isoladas destas amostras tais como C. laurentii (8.9%) e C. albidus (12.6 %), o qual também foi isolado de amostras do ar (5.4 %). Todas as amostras de C. neoformans foram sorotipo A (C. neoformans var. grubii). Em relação à avaliação do perfil de sensibilidade às drogas antifúngicas (5-fluorocitosina, fluconazol, itraconazol, anfotericina B e voriconazol) pelo método da microdiluição (EUCAST, 2002), destacou-se a presença de uma amostra com valor de concentração inibitória mínima (CIM) elevado para fluconazol, sendo de grande significância, uma vez tratar-se de isolado ambiental.